Xconomy

FEBRUARY 14, 2020

Post-marketing studies aim to identify side effects not observed in the first three phases of testing. This week, results of such a study led to the market withdrawal of weight-loss pill lorcaserin (Belviq). But the post-marketing study revealed a higher incidence of.

Study 77

Study Marketing San Diego Blogging 77

Xconomy

APRIL 22, 2020

Given the number of late-stage and mid-stage studies expected to report data in 2020—assuming they stay on track amid the COVID-19 pandemic—this could be a pivotal year for the field, said Isabelle de Cremoux, CEO and managing partner of Seventure Partners.

Class 138

Class Study Research Report 138

Xconomy

JULY 27, 2018

Eisai and partner Biogen released the highly anticipated details of an Alzheimer’s disease study they had already deemed positive, after an initial failure. In one sense, the study was the success they have claimed. A high dose of the drug appeared to have a positive impact on patients, compared to placebo.

Study 64

Study Invest San Diego Venture Capital 64

Both Sides of the Table

FEBRUARY 20, 2012

Tracy studied SEOMoz and several other online sources of SEO tips. So Tracy began keeping a blog about … (what else?) She became an authority on the topic and her blog helped her to both elevate her status in her industry as well as to bring great link juice to her website and improve her SEO.

Startup 363

Startup Entrepreneur SEO Venture Capital 363

Xconomy

APRIL 22, 2019

Swiss pharma giant Novartis has invested $75 million in a $142 million Series C round for San Diego-based Poseida, which is one of several companies developing what is meant to be a one-time, long-lasting treatment for multiple myeloma. Multiple myeloma affects about 300,000 Americans every year.

San Diego 83

San Diego Study Funding Invest 83

Xconomy

DECEMBER 20, 2018

New biopharma company Aristea Therapeutics has raised $15 million from Novo Holdings, the Danish investment company, and secured global rights to an investigational AstraZeneca drug that’s ready for Phase 2 study. The San Diego, CA, company made its public debut this week after starting up quietly earlier this year.

Develop 67

Develop Development San Diego Study 67

Xconomy

MAY 19, 2020

Amplyx Pharmaceuticals has completed enrollment in one mid-stage trial of its lead drug candidate, a new kind of antifungal treatment, and has finished treating the first patients in two more such studies.

San Diego 114

San Diego Funding Study Company 114

Both Sides of the Table

JANUARY 11, 2014

What Muhammad takes for granted is that every company that starts out immediately knows what he has learned over many years – that marketing is a long, hard slog of continually investing in repeatable, testable channels. ” Whenever I work with early-stage teams I have discussions about the meat & potatoes of online marketing.

Technical Review 384

Technical Review SEM SEO Marketing 384

Both Sides of the Table

APRIL 21, 2010

So it’s really hard to draw too many conclusions about whether the investment really makes sense because often you learn stuff in the fund raising about the future strategy of the company that might make you much more excited than somebody on the outside might be. Finally, a lot of people asking me about typos on my blog.

Venture Capital 265

Venture Capital Capital Email Blogging 265

Xconomy

AUGUST 17, 2016

She described the initial funding from Huapont as a strategic investment, as Histogen plans to work with the Chinese pharma conglomerate to make and distribute its lead product in China. The $6 million anchors Histogen’s plans to raise as much as $18 million in a Series D financing round, according to Histogen spokeswoman Eileen Brandt.

Invest 40

Invest San Diego Journal Technical Review 40

Both Sides of the Table

JULY 25, 2010

I recently read a book I’d highly recommend to every reader of this blog called “ Yes, 50 Scientifically Proven Ways to be Persuasive &# by Robert B. Rincon is part of the new breed of Seed Stage VCs and with the leadership of Jim Andelman has charted out the most authentic early-stage investment strategy in Southern California.

Guide 293

Guide Funding Venture Capital Technical Review 293

Xconomy

MARCH 27, 2020

Fallout from the spread of COVID-19 infections led several companies to declare this week that they would stop enrolling patients in clinical trials or postpone studies that have not yet started. The coronavirus pandemic has made it nearly impossible.

Study 95

Study Resource Sites San Diego 95

Xconomy

FEBRUARY 28, 2020

Making changes in the midst of the study was a no-no. Clinical trials have historically hewn to a rigid format. A trial is designed, conducted according to that design, and then results are analyzed. In recent years, regulators have showed openness to clinical trial designs intended to make drug testing more efficient.

News 89

News Design Study Examples 89

Both Sides of the Table

AUGUST 19, 2010

“A study by Microsoft showed just how lethal interruptions are to productivity. He also write a nice post on limiting email and managing on the important / urgent matrix from the perspective on a recovering ex investment banker. This comment and blog post prompted me to write a post that has been in my queue for a long time.

Product 301

Product Writing Email Tool 301

Both Sides of the Table

APRIL 13, 2011

Brad on blogging. How did you start blogging? “My My initial desire to blog came from something that’s always been my approach to investing – I’m a nerd and I love to play with the technology and part of my approach has really been to understand things both at a user level and at a reasonably deep tentacle level.

Venture Capital 288

Venture Capital Startup Technical Review Software Review 288

Xconomy

MAY 22, 2020

But Phase 1 clinical trials are small, and it’s unknown whether those early results can be replicated in larger studies. No major safety problems were reported and there were some indications that the injections elicited antibodies. Furthermore, Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Study 80

Study Report San Diego Blogging 80

Both Sides of the Table

APRIL 30, 2011

In the IAB study that revealed the graph above, brand advertisers indicated that their number one objective in online advertising was “creating awareness&# followed by “creating purchase intent&# or “likelihood to recommend&# the product. We are investing heavily in these changes. Holy Shiitake ! It has for decades.

Advertising 352

Advertising Media Social Media Screening 352

InfoChachkie

APRIL 25, 2011

Although many are entertaining, most fail to provide entrepreneurs with a sufficient return on their time investment. It has also influenced my thoughts, as evidenced by the six infoChachkie blog entries which reference Art. The second most referenced author on my blog, after Kawasaki, is Robert Cialdini, co-author of Yes!

Technical Review 279

Technical Review Blogging Class Entrepreneur 279

Both Sides of the Table

MAY 13, 2018

If you truly believe that you, your company and your products are exceptional and your company will be valuable then you’re actually doing them a FAVOR by helping them invest in your startup. If you don’t believe in your bones that you’re amazing then it’s no wonder you don’t want to sell them on making the investment.”

Venture Capital 332

Venture Capital Funding Startup Sales 332

Xconomy

AUGUST 14, 2020

Four years after its microbiome therapy failed in a mid-stage study, the company reported early positive data from a pivotal test of its treatment for a type of gut infection. The road of drug development is rife with detours and disappointments but Seres Therapeutics showed this week that course corrections can work.

Study 63

Study Course Report Company 63

Xconomy

SEPTEMBER 6, 2019

In presenting clinical data from a Phase 3 study. If MedCo’s cholesterol-lowering drug inclisiran wins FDA approval, it will become the third entry in a new class of medicines that block a cholesterol-boosting protein called PCSK9. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 84

Pricing Class Study Marketing 84

Xconomy

JANUARY 9, 2019

The Boston company, which counts diabetes drug giants Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ) among its investors and partners, says the capital will support Phase 3 studies of its device this year, and if all goes well, an application for FDA approval. Beta Bionics’s device is designed to mimic the role of.

Study 87

Study Design Capital Startup 87

Xconomy

FEBRUARY 22, 2019

Intercept (NASDAQ: ICPT ) reported interim data from a Phase 3 study showing its drug, obeticholic acid (OCA), reduced liver scarring in NASH patients. This week, one company, Intercept Pharmaceuticals, solidified its lead. But how much will being first to the finish line mean when all is said and done?

News 86

News Study Report San Diego 86

Xconomy

OCTOBER 1, 2018

The new VelosBio cash is earmarked for completing the work needed to proceed into human studies. These drugs are meant to provide a targeted strike to tumors, sparing healthy tissue. The specific cancers that VelosBio. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

San Diego 91

San Diego Incubator Class Study 91

Both Sides of the Table

FEBRUARY 17, 2019

By the way, I don’t spell check my blog posts either. The sort of thing I’m guessing you’ve studied for some time. Are you interested in looking at this investment where I’m on the board?” I’m on all of them and they’re all used in some form for business communications. I’m not an elitist a **e. I still sleep at night.

Email 250

Email Writing Conference Mobile 250

Both Sides of the Table

SEPTEMBER 8, 2009

I was reading Chris Dixon’s blog tonight. I came across this blog post about getting a computer science degree as the best degree for getting into venture capital or working at a VC-backed start up. I tell people regularly that I only invest in companies where the DNA is software. I had to laugh a bit reading it.

Startup 337

Startup Venture Capital Study Course 337

Xconomy

JUNE 13, 2019

The other, for autism, could start a Phase 1 study in 2020. The new Series B round will give San Francisco-based BlackThorn—a startup spun out of the Scripps Research Institute in 2013—the backing to run human tests of two experimental treatments. Those plans. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Tool 78

Tool Study Research Startup 78

Xconomy

AUGUST 17, 2016

Pharmstandard International, the Luxembourg-based investment arm of the Russian pharmaceutical giant Pharmstandard (and a first-time investor in Avelas), led the round. It was joined by two other new backers, Ervington Investments and Alexandria Venture Investments, and previous investors WuXi Healthcare Ventures, Bregua Corp.,

Avalon 40

Avalon San Diego Study Invest 40

Startup Professionals Musings

SEPTEMBER 27, 2011

I still plan to publish on this blog occasionally, as well as more frequently on my blogs at Forbes , Huffington Post , and others. Studies show that anyone can be an entrepreneur, but many won’t be happy as entrepreneurs. Blogging is a learning process as well as a sharing one. I’m sure you know what I mean.

Entrepreneur 96

Entrepreneur Startup Blogging Social Media 96

SoCal CTO

NOVEMBER 17, 2009

Sometimes I make a blog entry. Some days I respond to questions asked by folks like yourself, the press, or an entity doing a case study, i.e. Citrix, RIM, USC. I'd rather invest time investing in social media to drive traffic to our site. You've been blogging for a while, what are five good posts that I should check out?

Acquisition 170

Acquisition Customer Custom Ideas 170

Both Sides of the Table

MAY 25, 2013

Most top tier VCs return about 3x invested capital and outlier funds (the best of a vintage) might return 6-8x. It’s true this was much bigger in the dot com era but I’ve studied the data and know that over the past decade these numbers are right. You invest across many funds just as VCs invest across many companies.

Venture Capital 374

Venture Capital Entrepreneur Invest Funding 374

Xconomy

JUNE 21, 2018

Eidos will use the cash to fund studies of AG10 , a drug in mid-stage testing for transthyretin (TTR) amyloidosis, a progressive and fatal condition caused by the. The San Francisco company priced its IPO late Tuesday, selling 6.25 million shares at $17 each, which was on the high end of its projected $15 to $17 range.

Study 72

Study Startup Pricing Funding 72

Xconomy

DECEMBER 7, 2017

Proceeds will be used to advance Metacrine’s lead drug candidate, MET409, into first-in-human studies during the first half of 2018. Initial studies should be completed by the end of the year, the San Diego-based company said.

San Diego 49

San Diego Study Develop Development 49

Startup Professionals Musings

NOVEMBER 2, 2013

According to a study of 1700 CEOs last year, only 60% of companies today use social media for marketing, and only 12% of those feel that they are using it effectively. A most valuable tool is WordPress or TypePad for blogging. Maybe it’s time to sign up for a few free Webinars, or even invest in an expert consultant in this area.

Social Media 106

Social Media Media Startup Social Network 106

Xconomy

DECEMBER 21, 2016

After years of research, frustration, hype, and millions (sometimes hundreds of millions) of dollars invested, a drug program boils down to the clinical data—usually from big, late-stage studies—that can sometimes make or break a company. [Editor’s note: Alex Lash and Frank Vinluan contributed to this report.]

Study 40

Study Report Research Invest 40

Southern California Edison Blog

JUNE 30, 2021

According to a study conducted by CompTIA, 46 percent of enterprises who transitioned IT functions to a managed services provider saw a 25 percent or more reduction in their annual IT costs. Partnering with a local MNSP also enables more predictable cost structures, so companies can better budget and plan around IT and network investments.

Networking 98

Networking Services Culver City Southern California 98

Xconomy

JANUARY 11, 2017

A recent study by EdSurge , an edtech information firm, shows venture funding for U.S. billion invested in 198 deals in 2015, according to EdSurge. education tech companies totaled $1.03 billion (across 138 deals) in 2016. Those numbers are down from the $1.45

Funding 40

Funding Education Venture Capital Study 40